Tolerance and adverse events of treatment with acetylcholinesterase inhibitors in a clinical sample of patients with very slight and mild Alzheimer's disease over a six-month period;Tolerancia y acontecimientos adversos del tratamiento con inhibidores de la acetilcolinesterasa en una muestra clínica de pacientes con enfermedad de Alzheimer de gravedad mínima y leve durante un período de seis meses

Revista de Neurologia

Volumn 36, Issue 5, 2003, Pages 421-424

  Turon Estrada, Antoni ^a   Lopez Pousa S ^a   Gelada Batlle, E ^a   Garre Olmo, J ^a   Lozano Gallego, M ^a   Hernandez Ferrandiz M ^a   Fajardo Tibau, C ^a   Morante Munoz V ^a   Vilalta Franch, J ^a  

^a HOSPITAL SANTA CATERINA   (Spain)

Author keywords

Adverse events; Alzheimer's disease; Anticholinesterases; Tolerance

Indexed keywords

ALPHA TOCOPHEROL; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ANXIOLYTIC AGENT; CALCIUM ANTAGONIST; CHOLINESTERASE INHIBITOR; DIURETIC AGENT; DONEPEZIL; HYPNOTIC SEDATIVE AGENT; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; VITAMIN;

ACETYLCHOLINE RELEASE; ADULT; AGED; AGITATION; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; CONFUSION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HALLUCINATION; HUMAN; INCIDENCE; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SOMNOLENCE; STATISTICAL ANALYSIS; VERTIGO;

EID: 0037366166     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3605.2002416     Document Type: Article

References (20)

1. Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 2: 1403.
2. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory disfunction. Science 1982; 217: 408-17.
3. Holttum JR, Gershon S. The cholinergic model of dementia, Alzheimer's type: progression form the unitary transmitter concept. Dementia 1992; 3: 174-85.
4. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999; 66: 137-47.
5. Ens A, Florsheim P. Cholinesterase inhibitors: an overview of their mechanism of action. In Becker R, Giacobini E, eds. Alzheimer's disease: from molecular biology to therapy. Boston (MA): Bikhauser; 1996. p. 211-5.
6. López-Pousa S, Lombardía-Fernández C. Tratamiento de la enfermedad de Alzheimer: fármacos inhibidores de la enzima acetilcolinesterasa. Neurología 1999; 14: 180-8.
7. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease: The Tacrine Study Group. JAMA 1994; 271: 985-91.
8. Corey-Bloom J, Anand R, Veach H for the ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastiginine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderate severe Alzheimer's disease. Int N Geriatr Psychopharmacol 1998; 1: 55-65.
9. Rogers SL, Farlow MR, Doody RS and the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trail of Donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-45.
10. Wilcock GK, Lilenfeld S, Galantamine International-1 Study Group. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Br Med J 2000; 321: 1-7.
11. Imbimbo BP. Pharmacodynamic-Tolerability Relationships of Cholinesterase Inhibitors for Alzheimer's disease. CNS Drugs 2001; 15: 375-90.
12. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4 ed (DSM IV). Washington DC: American Psychiatric Association; 1995.
13. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939-44.
14. Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma S. CAMDEX. A standarized instrument for the diagnosis of mental disorders in the elderly with special reference to the early detection of dementia. Br J Psychiatry 1986; (Suppl 6): S10-6.
15. Llinàs-Reglà J, López-Pousa S, Vilalta-Franch J. CAMDEX. Adaptación y validación españolas. Barcelona: Ancora; 1991.
16. Wilkinson D, Passmore P, Potocnik F, Maud C, Hock C. Donepezil compared with rivastigmine in Alzheimer's disease: similar efficacy but better tolerability, and physician and caregiver satisfaction in a multinational randomized trial. Poster XVII World Congress of Neurology (WCN). London, UK; June 17-22, 2001.
17. Eagger SA, Harvet RJ. Clinical heterogeneity: responders to cholinergic therapy. Alzheimer Dis Assoc Disord 1995; 9 (Suppl 2): 37-42.
18. McGowan SH, Wilcock G, Scott M. Effect of gender and apolipoprotein E genotype on response to acetylcholinesterase therapy in Alzheimer's disease. Nt J Geriatr Psychiatr 1998; 13: 625-30.
19. Weinstock M. Selectividad de la inhibición de la colinesterasa. Implicaciones clínicas para el tratamiento de la enfermedad de Alzheimer. CNS Drugs 1999; 12: 307-24.
20. Ray DE. Chronic effects of low level exposure to anticholinesterases-a mechanistic review. Toxicol Lett 1998; 102-3: 527-33.